Hanne Vebert Olesen

Hanne Vebert Olesen

Auto-generated profile, based on publicly available information

Hanne Vebert Olesen

The Danish Cystic Fibrosis Cohort, Denmark; Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Denmark

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
TQTavs Qvist
Tavs Qvist
DTDavid Taylor-Robinson
David Taylor-Robinson
EWElisabeth Waldmann
Elisabeth Waldmann
HOHanne Vebert Olesen
Hanne Vebert Olesen
CHChristine Rønne Hansen
Christine Rønne Hansen
TPTania Pressler
Tania Pressler
To better understand the relative effects of infection with nontuberculous mycobacteria and Gram negative bacteria on lung function decline in cystic fibrosis, we assessed the impact of each infection in a Danish setting. Longitudinal registry study of 432 patients with cystic fibrosis contributing 53,771 lung function measures between 1974 and 2014. We used a mixed effects model with longitudinally structured correlation, while adjusting for clinically important covariates. Infections with a significant impact on rate of decline in %FEV1 were Mycobacterium abscessus complex with -2.22% points per year (95% CI -3.21 to -1.23), Burkholderia cepacia complex -1.95% (95% CI -2.51 to -1.39), Achromobacterxylosoxidans -1.55% (95% CI -2.21 to -0.90), and Pseudomonas aeruginosa -0.95% (95% CI -1.24 to -0.66). Clearing M. abscessus complex was associated with a change to a slower decline, similar in magnitude to the pre-infection slope. In a national population we have demonstrated the impact on lung function of each chronic CF pathogen. M. abscessus complex was associated with the worst impact on lung function. Eradication of M. abscessus complex may significantly improve lung function.

1 March 2020 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
HOHanne V Olesen
Hanne V Olesen
PDPavel Drevinek
Pavel Drevinek
VGVincent A Gulmans
Vincent A Gulmans
Elpis HatziagorouElpis Hatziagorou
Elpis Hatziagorou
AJAndreas Jung
Andreas Jung
AZAnna Zolin
Anna Zolin

1 December 2006 in Clinical Immunology
Verified
Journal Article
Closed access
HOH.V. Olesen
H.V. Olesen
JJJ.C. Jensenius
J.C. Jensenius
RSR. Steffensen
R. Steffensen
STSteffen Thiel
Steffen Thiel
PSP.O. Schiøtz
P.O. Schiøtz

20 October 2006 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
HOHanne Vebert Olesen
Hanne Vebert Olesen
LNLars P. Nielsen
Lars P. Nielsen
PSPeter Oluf Schiotz
Peter Oluf Schiotz

29 July 2010 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
HOHanne Vebert Olesen
Hanne Vebert Olesen
TPTacjana Pressler
Tacjana Pressler
LHLena Hjelte
Lena Hjelte
LMLena Mared
Lena Mared
ALAnders Lindblad
Anders Lindblad
OCon behalf of the Scandinavian Cystic Fibrosis Study Consortium
on behalf of the Scandinavian Cystic Fibrosis Study Consortium

20 November 2023 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
BNBibi Uhre Nielsen
Bibi Uhre Nielsen
MOMette Frahm Olsen
Mette Frahm Olsen
IMInger Hee Mabuza Mathiesen
Inger Hee Mabuza Mathiesen
TPTacjana Pressler
Tacjana Pressler
CRChristian Ritz
Christian Ritz
DFDaniel Faurholt-Jepsen
Daniel Faurholt-Jepsen
Elexacaftor/tezacaftor/ivacaftor (ETI) has improved the clinical status of individuals with cystic fibrosis (CF), however, whether ETI impacts glucose tolerance remains unknown. We aimed to study the change in glycated hemoglobin (HbA1c) and CF related diabetes (CFRD) status after initiation of ETI. We included individuals ≥12 years treated with ETI in Denmark in a longitudinal observational study. HbA1c was measured at baseline, 3, 6, 9 and 12 months after treatment initiation. Change in HbA1c was assessed in mixed models adjusted for age, sex, glucose tolerance and prior CFTR modulator treatment. In a sub-population with CFRD, we assessed the change in insulin usage, hypoglycemic events and the 30-day continuous glucose monitoring (CGM) parameters (i.e., average blood glucose, time below (≤3.9 mM) and above (>10.0 mM) normal range, and the variation in glucose) after 12 months of treatment. Among 321 individuals with CF, HbA1c declined by 2.1 mmol/mol [95 % confidence interval (CI): -2.6; -1.5 mmol/mol] after 3 months and by 2.3 mmol/mol [95 %CI: -2.8; -1.9 mmol/mol] after 12 months of ETI treatment. The decline was independent of glucose tolerance status at baseline. In 26 individuals with CFRD at baseline, the mean decline in HbA1c was 3.6 mmol/mol [95 %CI: -6.9; -0.4 mmol/mol] after 12 months, but we did not observe any change in insulin usage, weekly number of hypoglycemic events or CGM parameters. In the Danish CF cohort, HbA1c declined over 12 months of ETI treatment, however, among a subset with CFRD, we observed no change in insulin usage and CGM glucose levels.